Literature DB >> 21861777

Measurements of immune responses for establishing correlates of vaccine protection against HIV.

Wendy A Burgers1, Amapola Manrique, David Masopust, Lyle R McKinnon, Matthew R Reynolds, Morgane Rolland, Catherine Blish, Gerald K Chege, Rhonda Curran, William Fischer, Carolina Herrera, D Noah Sather.   

Abstract

Well-defined correlates of protective immunity are an essential component of rational vaccine development. Despite years of basic science and three HIV vaccine efficacy trials, correlates of immunological protection from HIV infection remain undefined. In December 2010, a meeting of scientists engaged in basic and translational work toward developing HIV-1 vaccines was convened. The goal of this meeting was to discuss current opportunities and optimal approaches for defining correlates of protection, both for ongoing and future HIV-1 vaccine candidates; specific efforts were made to engage young scientists. We discuss here the highlights from the meeting regarding the progress made and the way forward for a protective HIV-1 vaccine.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21861777      PMCID: PMC3380381          DOI: 10.1089/AID.2011.0239

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  46 in total

1.  Antibody levels and immune memory 23 years after primary plasma-derived hepatitis B vaccination: results of a randomized placebo-controlled trial cohort from China where endemicity is high.

Authors:  Qian Wu; Gui-Hua Zhuang; Xue-Liang Wang; Li-Rong Wang; Na Li; Min Zhang
Journal:  Vaccine       Date:  2011-01-28       Impact factor: 3.641

Review 2.  Correlates of protection induced by vaccination.

Authors:  Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2010-05-12

Review 3.  The quest for a T cell-based immune correlate of protection against HIV: a story of trials and errors.

Authors:  Richard A Koup; Barney S Graham; Daniel C Douek
Journal:  Nat Rev Immunol       Date:  2010-12-17       Impact factor: 53.106

4.  Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.

Authors:  Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden
Journal:  N Engl J Med       Date:  2010-11-23       Impact factor: 91.245

5.  Implications of HIV PrEP trials results.

Authors:  Fulvia Veronese; Peter Anton; Courtney V Fletcher; Victor DeGruttola; Ian McGowan; Stephen Becker; Sheryl Zwerski; David Burns
Journal:  AIDS Res Hum Retroviruses       Date:  2010-12-12       Impact factor: 2.205

6.  HIV-1 vaccines and adaptive trial designs.

Authors:  Lawrence Corey; Gary J Nabel; Carl Dieffenbach; Peter Gilbert; Barton F Haynes; Margaret Johnston; James Kublin; H Clifford Lane; Giuseppe Pantaleo; Louis J Picker; Anthony S Fauci
Journal:  Sci Transl Med       Date:  2011-04-20       Impact factor: 17.956

7.  Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine.

Authors:  Peter Gilbert; Maggie Wang; Terri Wrin; Chris Petropoulos; Marc Gurwith; Faruk Sinangil; Patricia D'Souza; Isaac R Rodriguez-Chavez; Allan DeCamp; Mike Giganti; Phillip W Berman; Steve G Self; David C Montefiori
Journal:  J Infect Dis       Date:  2010-08-15       Impact factor: 5.226

8.  Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies.

Authors:  Michael Vaine; Shixia Wang; Qin Liu; James Arthos; David Montefiori; Paul Goepfert; M Juliana McElrath; Shan Lu
Journal:  PLoS One       Date:  2010-11-09       Impact factor: 3.240

9.  Pre-exposure prophylaxis and the promise of combination prevention approaches.

Authors:  Susan P Buchbinder; Albert Liu
Journal:  AIDS Behav       Date:  2011-04

10.  Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial.

Authors:  Morgane Rolland; Sodsai Tovanabutra; Allan C deCamp; Nicole Frahm; Peter B Gilbert; Eric Sanders-Buell; Laura Heath; Craig A Magaret; Meera Bose; Andrea Bradfield; Annemarie O'Sullivan; Jacqueline Crossler; Teresa Jones; Marty Nau; Kim Wong; Hong Zhao; Dana N Raugi; Stephanie Sorensen; Julia N Stoddard; Brandon S Maust; Wenjie Deng; John Hural; Sheri Dubey; Nelson L Michael; John Shiver; Lawrence Corey; Fusheng Li; Steve G Self; Jerome Kim; Susan Buchbinder; Danilo R Casimiro; Michael N Robertson; Ann Duerr; M Juliana McElrath; Francine E McCutchan; James I Mullins
Journal:  Nat Med       Date:  2011-02-27       Impact factor: 53.440

View more
  10 in total

Review 1.  Recent developments in clinical trial designs for HIV vaccine research.

Authors:  Laura Richert; Edouard Lhomme; Catherine Fagard; Yves Lévy; Geneviève Chêne; Rodolphe Thiébaut
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 2.  HIV vaccine development: strategies for preclinical and clinical investigation.

Authors:  Stuart Z Shapiro
Journal:  AIDS Res Hum Retroviruses       Date:  2013-03-08       Impact factor: 2.205

3.  Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.

Authors:  Josephine H Cox; Maria G Ferrari; Patricia Earl; James R Lane; Linda L Jagodzinski; Victoria R Polonis; Ellen G Kuta; Jean D Boyer; Silvia Ratto-Kim; Leigh-Anne Eller; Doan-Trang Pham; Lydia Hart; David Montefiori; Guido Ferrari; Stephanie Parrish; David B Weiner; Bernard Moss; Jerome H Kim; Deborah Birx; Thomas C VanCott
Journal:  Vaccine       Date:  2012-01-09       Impact factor: 3.641

4.  Splenic priming of virus-specific CD8 T cells following influenza virus infection.

Authors:  Damian L Turner; Kara L Bickham; Donna L Farber; Leo Lefrançois
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

5.  Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model.

Authors:  Gerald K Chege; Wendy A Burgers; Helen Stutz; Ann E Meyers; Rosamund Chapman; Agano Kiravu; Rubina Bunjun; Enid G Shephard; William R Jacobs; Edward P Rybicki; Anna-Lise Williamson
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103

6.  Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults.

Authors:  Peter Hayes; Jill Gilmour; Andrea von Lieven; Dilbinder Gill; Lorna Clark; Jakub Kopycinski; Hannah Cheeseman; Amy Chung; Galit Alter; Len Dally; Devika Zachariah; Angela Lombardo; James Ackland; Eddy Sayeed; Akil Jackson; Marta Boffito; Brian Gazzard; Patricia E Fast; Josephine H Cox; Dagna Laufer
Journal:  Clin Vaccine Immunol       Date:  2013-01-23

7.  Interplay between HIV-1 and Host Genetic Variation: A Snapshot into Its Impact on AIDS and Therapy Response.

Authors:  Raghavan Sampathkumar; Elnaz Shadabi; Ma Luo
Journal:  Adv Virol       Date:  2012-05-16

8.  Optimizing viable leukocyte sampling from the female genital tract for clinical trials: an international multi-site study.

Authors:  Lyle R McKinnon; Sean M Hughes; Stephen C De Rosa; Jeffrey A Martinson; Jill Plants; Kirsten E Brady; Pamela P Gumbi; Devin J Adams; Lucia Vojtech; Christine G Galloway; Michael Fialkow; Gretchen Lentz; Dayong Gao; Zhiquan Shu; Billy Nyanga; Preston Izulla; Joshua Kimani; Steve Kimwaki; Alfred Bere; Zoe Moodie; Alan L Landay; Jo-Ann S Passmore; Rupert Kaul; Richard M Novak; M Juliana McElrath; Florian Hladik
Journal:  PLoS One       Date:  2014-01-15       Impact factor: 3.240

Review 9.  Anti-Tat Immunity in HIV-1 Infection: Effects of Naturally Occurring and Vaccine-Induced Antibodies Against Tat on the Course of the Disease.

Authors:  Aurelio Cafaro; Antonella Tripiciano; Orietta Picconi; Cecilia Sgadari; Sonia Moretti; Stefano Buttò; Paolo Monini; Barbara Ensoli
Journal:  Vaccines (Basel)       Date:  2019-08-26

10.  Improving Adherence to Post-Cervical Biopsy Sexual Abstinence in Kenyan Female Sex Workers.

Authors:  Julie Lajoie; Genevieve Boily-Larouche; Kelsie Doering; Juliana Cheruiyot; Julius Oyugi; Kristina Broliden; Joshua Kimani; Keith R Fowke
Journal:  Am J Reprod Immunol       Date:  2016-05-24       Impact factor: 3.886

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.